Jade Biosciences Statistics
Total Valuation
JBIO has a market cap or net worth of $1.30 billion. The enterprise value is $969.11 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
JBIO has 49.32 million shares outstanding.
| Current Share Class | 49.32M |
| Shares Outstanding | 49.32M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +36.39% |
| Owned by Insiders (%) | 0.36% |
| Owned by Institutions (%) | 78.73% |
| Float | 32.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.92 |
| P/TBV Ratio | 3.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.09, with a Debt / Equity ratio of 0.00.
| Current Ratio | 21.09 |
| Quick Ratio | 20.33 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -31.54 |
Financial Efficiency
Return on equity (ROE) is -89.18% and return on invested capital (ROIC) is -36.01%.
| Return on Equity (ROE) | -89.18% |
| Return on Assets (ROA) | -33.59% |
| Return on Invested Capital (ROIC) | -36.01% |
| Return on Capital Employed (ROCE) | -34.07% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.82M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, JBIO has paid $58,000 in taxes.
| Income Tax | 58,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 16.59 |
| 200-Day Moving Average | 12.33 |
| Relative Strength Index (RSI) | 81.00 |
| Average Volume (20 Days) | 792,286 |
Short Selling Information
The latest short interest is 3.06 million, so 6.21% of the outstanding shares have been sold short.
| Short Interest | 3.06M |
| Short Previous Month | 1.25M |
| Short % of Shares Out | 6.21% |
| Short % of Float | 9.36% |
| Short Ratio (days to cover) | 4.51 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -113.54M |
| Pretax Income | -127.35M |
| Net Income | -100.14M |
| EBITDA | -113.52M |
| EBIT | -113.54M |
| Earnings Per Share (EPS) | -$3.19 |
Full Income StatementBalance Sheet
The company has $336.16 million in cash and $851,000 in debt, giving a net cash position of $335.31 million or $6.80 per share.
| Cash & Cash Equivalents | 336.16M |
| Total Debt | 851,000 |
| Net Cash | 335.31M |
| Net Cash Per Share | $6.80 |
| Equity (Book Value) | 332.52M |
| Book Value Per Share | 6.74 |
| Working Capital | 332.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$94.69 million and capital expenditures -$196,000, giving a free cash flow of -$94.89 million.
| Operating Cash Flow | -94.69M |
| Capital Expenditures | -196,000 |
| Depreciation & Amortization | 26,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -94.89M |
| FCF Per Share | -$1.92 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |